



Biomarkers in Colorectal Cancer

Guest Editors:

Prof. Dr. Enrico Mini

Department of Health Sciences,
University of Florence, Florence,
Italy

Dr. Stefania Nobili

Department of Neurosciences,
Imaging and Clinical Sciences,
"G. d'Annunzio" University of
Chieti-Pescara, Chieti, Italy

Deadline for manuscript
submissions:

closed (31 October 2018)

Message from the Guest Editors

Dear Colleagues


Colorectal cancer is the third cancer, both in terms of incidence and mortality in Western countries. Currently, molecular biomarkers play an important role in the detection and treatment of colorectal cancer patients. Molecular biomarkers are useful in recognizing colorectal cancer susceptibility or in the screening and diagnosis of early stages of the disease. The presence or absence of specific prognostic and predictive tumour biomarkers lead to a more rational selection of pharmacological treatments for colorectal cancer with consequent improvements in outcome. Molecular biomarkers predictive of drug toxicity are also available and help clinicians in the choice of the safest drug treatment for each patient. In this Special Issue, the current knowledge, as well as the future perspectives on the role of tumour biomarkers in colorectal cancer screening, diagnosis, treatment and follow-up, will be discussed.

Prof. Dr. Enrico Mini

Dr. Stefania Nobili

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Senior Vice President and Director, Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Professor of Medicine Chief, Section of Hematologic Malignancies, Associate Director for Clinical Research, Division of Hematologic Malignancies and Cellular Therapy Duke Cancer Institute, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[@JPM_MDPI](https://twitter.com/JPM_MDPI)